<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
 xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:owl="http://www.w3.org/2002/07/owl#"
 xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"
 xml:base="http://www.reactome.org/biopax/91/9682385#">
<owl:Ontology rdf:about="">
 <owl:imports rdf:resource="http://www.biopax.org/release/biopax-level3.owl#" />
</owl:Ontology>

<bp:PathwayStep rdf:ID="PathwayStep27">
 <bp:stepProcess rdf:resource="#BiochemicalReaction13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep28">
 <bp:stepProcess rdf:resource="#Pathway16" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep25">
 <bp:stepProcess rdf:resource="#BiochemicalReaction12" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep26">
 <bp:stepProcess rdf:resource="#Pathway15" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep29">
 <bp:stepProcess rdf:resource="#BiochemicalReaction14" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep30">
 <bp:stepProcess rdf:resource="#Pathway17" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep31">
 <bp:stepProcess rdf:resource="#BiochemicalReaction15" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep34">
 <bp:stepProcess rdf:resource="#BiochemicalReaction18" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep35">
 <bp:stepProcess rdf:resource="#BiochemicalReaction19" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep32">
 <bp:stepProcess rdf:resource="#BiochemicalReaction16" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep33">
 <bp:stepProcess rdf:resource="#BiochemicalReaction17" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep38">
 <bp:stepProcess rdf:resource="#BiochemicalReaction22" />
 <bp:stepProcess rdf:resource="#Catalysis2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep39">
 <bp:stepProcess rdf:resource="#BiochemicalReaction23" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep36">
 <bp:stepProcess rdf:resource="#BiochemicalReaction20" />
 <bp:stepProcess rdf:resource="#Catalysis1" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep37">
 <bp:stepProcess rdf:resource="#BiochemicalReaction21" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep41">
 <bp:stepProcess rdf:resource="#BiochemicalReaction25" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep42">
 <bp:stepProcess rdf:resource="#BiochemicalReaction26" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep40">
 <bp:stepProcess rdf:resource="#BiochemicalReaction24" />
 <bp:stepProcess rdf:resource="#Catalysis3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep45">
 <bp:stepProcess rdf:resource="#BiochemicalReaction29" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep46">
 <bp:stepProcess rdf:resource="#Catalysis4" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction30" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep43">
 <bp:stepProcess rdf:resource="#BiochemicalReaction27" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep44">
 <bp:stepProcess rdf:resource="#BiochemicalReaction28" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep49">
 <bp:stepProcess rdf:resource="#Pathway18" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep47">
 <bp:stepProcess rdf:resource="#BiochemicalReaction31" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep48">
 <bp:stepProcess rdf:resource="#BiochemicalReaction32" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep52">
 <bp:stepProcess rdf:resource="#BiochemicalReaction34" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep53">
 <bp:stepProcess rdf:resource="#BiochemicalReaction35" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep50">
 <bp:stepProcess rdf:resource="#Catalysis5" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction33" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep51">
 <bp:stepProcess rdf:resource="#Pathway19" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep56">
 <bp:stepProcess rdf:resource="#BiochemicalReaction37" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep57">
 <bp:stepProcess rdf:resource="#BiochemicalReaction38" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep54">
 <bp:stepProcess rdf:resource="#Pathway20" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep55">
 <bp:stepProcess rdf:resource="#Catalysis6" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction36" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep58">
 <bp:stepProcess rdf:resource="#BiochemicalReaction39" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep59">
 <bp:stepProcess rdf:resource="#Catalysis7" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction40" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep63">
 <bp:stepProcess rdf:resource="#BiochemicalReaction43" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep64">
 <bp:stepProcess rdf:resource="#BiochemicalReaction44" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep61">
 <bp:stepProcess rdf:resource="#BiochemicalReaction42" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep62">
 <bp:stepProcess rdf:resource="#Pathway21" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep67">
 <bp:stepProcess rdf:resource="#BiochemicalReaction47" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep68">
 <bp:stepProcess rdf:resource="#BiochemicalReaction48" />
 <bp:stepProcess rdf:resource="#Catalysis8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep65">
 <bp:stepProcess rdf:resource="#BiochemicalReaction45" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep66">
 <bp:stepProcess rdf:resource="#BiochemicalReaction46" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep60">
 <bp:stepProcess rdf:resource="#BiochemicalReaction41" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway1">
 <bp:pathwayOrder rdf:resource="#PathwayStep30" />
 <bp:pathwayOrder rdf:resource="#PathwayStep51" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1" />
 <bp:pathwayOrder rdf:resource="#PathwayStep54" />
 <bp:pathwayOrder rdf:resource="#PathwayStep49" />
 <bp:pathwayComponent rdf:resource="#Pathway2" />
 <bp:pathwayComponent rdf:resource="#Pathway17" />
 <bp:pathwayComponent rdf:resource="#Pathway18" />
 <bp:pathwayComponent rdf:resource="#Pathway19" />
 <bp:pathwayComponent rdf:resource="#Pathway20" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 signaling in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 is a type III receptor tyrosine kinase (RTK). The extracellular domain consists of 5 immunoglobulin (Ig) domains that contribute to dimerization and ligand binding. The intracellular region has a juxtamembrane domain that plays a role in autoinhibiting the receptor in the absence of ligand, and a bi-lobed kinase region with an activation loop and the catalytic cleft (reviewed in Klug et al, 2018). Signaling through FLT3 occurs after ligand-induced dimerization and transautophosphorylation, and promotes signaling through the MAP kinase, PI3K and STAT5 pathways, among others. FLT3 signaling promotes cellular proliferation and differentiation and contributes to haematopoeisis. FLT3 is mutated in up to 30% of acute myeloid leukemias. ~25% of the FLT3 mutations in AML cases occur as internal tandem duplications (ITDs) either in the juxtamembrane domain region encoded by exon 14 or the tyrosine kinase domain (TKD), while ~7-10% of AML cases contain FLT3 missense mutations in the TKD (reviewed in Klug et al, 2018; Daver et al, 2019). These mutations all support ligand-independent activation of the receptor and result in constitutive activation and signaling (Zheng et al, 2004; reviewed in Klug et al, 2018; Kazi and Roonstrand, 2019). In rare cases, the FLT3 locus is also subject to translocations that generate constitutively active fusion proteins (reviewed in Kazi and Roonstrand, 2019). Oncogenic FLT3 activity can be targeted with tyrosine kinase inhibitors, although resistance often arises due to secondary mutations or activation of bypass pathways (reviewed in Staudt et al, 2018; Daver et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway2">
 <bp:pathwayOrder rdf:resource="#PathwayStep16" />
 <bp:pathwayOrder rdf:resource="#PathwayStep28" />
 <bp:pathwayOrder rdf:resource="#PathwayStep14" />
 <bp:pathwayOrder rdf:resource="#PathwayStep26" />
 <bp:pathwayOrder rdf:resource="#PathwayStep18" />
 <bp:pathwayOrder rdf:resource="#PathwayStep20" />
 <bp:pathwayOrder rdf:resource="#PathwayStep12" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2" />
 <bp:pathwayOrder rdf:resource="#PathwayStep24" />
 <bp:pathwayOrder rdf:resource="#PathwayStep10" />
 <bp:pathwayOrder rdf:resource="#PathwayStep4" />
 <bp:pathwayOrder rdf:resource="#PathwayStep22" />
 <bp:pathwayOrder rdf:resource="#PathwayStep6" />
 <bp:pathwayOrder rdf:resource="#PathwayStep8" />
 <bp:pathwayComponent rdf:resource="#Pathway3" />
 <bp:pathwayComponent rdf:resource="#Pathway4" />
 <bp:pathwayComponent rdf:resource="#Pathway5" />
 <bp:pathwayComponent rdf:resource="#Pathway6" />
 <bp:pathwayComponent rdf:resource="#Pathway7" />
 <bp:pathwayComponent rdf:resource="#Pathway8" />
 <bp:pathwayComponent rdf:resource="#Pathway9" />
 <bp:pathwayComponent rdf:resource="#Pathway12" />
 <bp:pathwayComponent rdf:resource="#Pathway13" />
 <bp:pathwayComponent rdf:resource="#Pathway10" />
 <bp:pathwayComponent rdf:resource="#Pathway11" />
 <bp:pathwayComponent rdf:resource="#Pathway16" />
 <bp:pathwayComponent rdf:resource="#Pathway14" />
 <bp:pathwayComponent rdf:resource="#Pathway15" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Drug resistance of FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 is mutated in ~30% of acute myeloid leukemias (AML), with internal tandem duplications (ITDs) representing the majority of these mutations and activating point mutants occurring at lower frequency. FLT3 mutations also occur at lower rates in other cancers (reviewed in Kazi and Roonstrand, 2018; Daver et al, 2019; Larroas-Garcia and Baer, 2017). Mutation of FLT3 has been identified as a driver in progression of AML and in consequence is a promising therapeutic target. A number of first and second generation inhibitors have been demonstrated to have activity against FLT3, but accumulation of secondary mutations leads to the development of resistance. These secondary mutations further shift the equilibrium of the receptor toward the activated state, making even the second-generation type II TKIs less effective. In consequence, considerable effort is devoted to discovery of type II and, in particular, type I TKIs that are active against highly activated FLT3 alleles (reviewed in Daver et al, 2019; Staudt et al, 2018; Lim et al, 2017; Klug et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence19">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway3">
 <bp:pathwayOrder rdf:resource="#PathwayStep3" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence3" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KW2449-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KW-2449 is a second generation, type I aurora kinase and FLT3 tyrosine kinase inhibitor, Despite effectiveness against a number of FLT3 mutant alleles, it has been withdrawn from development due to poor pharmacodynamics (reviewed in Larrosa-Garcia and Baer, 2017; Kazi and Roonstrand, 2019). This pathway describes FLT3 mutants that are resistant to inhibition by KW-2449.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway4">
 <bp:pathwayOrder rdf:resource="#PathwayStep5" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction2" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence5" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">midostaurin-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Midostaurin, also known as PKC412, is a type I tyrosine kinase inhibitor with activity against FLT3 (reviewed in Kazi and Roonstrand, 2019; Luskin and DeAngelo, 2017). This pathway describes FTL3 mutants that are resistant to inhibition by midostaurin.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway5">
 <bp:pathwayOrder rdf:resource="#PathwayStep7" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction3" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence7" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">sunitinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sunitinib is a first generation type II tyrosine kinase inhibitor with broad specifity for receptor tyrosine kinases, including FLT3. This pathway describes FLT3 mutants that show resistance to sunitinib-mediated inhibition (reviewed in Kazi and Roonstrand, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway6">
 <bp:pathwayOrder rdf:resource="#PathwayStep9" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction4" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence9" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pexidartinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pexidartinib is a type II tyrosine kinase inhibitor that is active against FLT3, including the quizartinib-resistant gatekeeper mutation F691L. Activating mutations at TKD aspartic acid residue 835 are resistant to pexidartinib-mediated inhibition, however (Smith et al, 2015a, b). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway7">
 <bp:pathwayOrder rdf:resource="#PathwayStep11" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction5" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence11" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">tandutinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tandutinib, also known as MLN519, is a type II tyrosine kinase inhibitor with activity against FLT3 (Clark et al, 2004; reviewed in Staudt et al, 2018; Daver et al, 2019). This pathway describes FLT3 mutants that are resistant to tandutinib-mediated inhibition.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway8">
 <bp:pathwayOrder rdf:resource="#PathwayStep13" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction6" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence13" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">tamatinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tamatinib is a type I tyrosine kinase inhibitor with activity against FLT3. This pathway describes FLT3 mutants that are resistant to inhibition by tamatinib (Nguyen et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence12">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway9">
 <bp:pathwayOrder rdf:resource="#PathwayStep15" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction7" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence15" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">sorafenib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib is a first generation type II tyrosine kinase inhibitor with broad specificity for receptor tyrosine kinases including FLT3. This pathway describes FLT3 mutants that are resistant to sorafenib-mediated inhibition (Nguyen et al 2017; Linblad et al, 2017;reviewed in Kazi and Roonstrand, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence11">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence14">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence13">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence16">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence15">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence18">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence17">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence10">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction19">
 <bp:evidence rdf:resource="#Evidence36" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions recruit PIK3R1 through phosphorylated GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction17">
 <bp:evidence rdf:resource="#Evidence34" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of FLT3 fusion proteins</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction18">
 <bp:evidence rdf:resource="#Evidence35" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 dissociates from FLT3 fusion proteinsp-</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway12">
 <bp:pathwayOrder rdf:resource="#PathwayStep21" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction10" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence21" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">quizartinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Quizartinib is a type II tyrosine kinase inhibitor that is in phase III clinical trials for treatment of acute myeloid leukemias with FLT3 internal tandem duplications (ITDs). This pathway describes FLT3 mutants that display resistance to quizartinib (reviewed in Kazi and Roonstrand, 2019; Daver et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction15">
 <bp:evidence rdf:resource="#Evidence32" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions activate STAT5</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway13">
 <bp:pathwayOrder rdf:resource="#PathwayStep23" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction11" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence23" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">semaxanib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Semaxanib, also known as SU5614, is an investigational type I tyrosine kinase inhibitor with activity against a wide range of receptor tyrosine kinases. It is not currently approved for clinical use. This pathway describes FLT3 mutants that show resistance to semaxanib-mediated inhibition (Yee et al, 2002; Spiekermann et al, 2003).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction16">
 <bp:evidence rdf:resource="#Evidence33" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions recruit PIK3CA through PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway10">
 <bp:pathwayOrder rdf:resource="#PathwayStep17" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction8" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence17" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">lestaurtinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Lestaurtinib is a first-generation, type I tyrosine kinase inhibitor with activity against a range of receptor tyrosine kinases including FLT3 (reviewed in Larrosa-Garcia and Baer, 2017; Staudt et al, 2018; Daver et al, 2019). This pathway describes FLT3 mutants that are resistant to lestaurtinib-mediated inhibition.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction13">
 <bp:evidence rdf:resource="#Evidence28" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ponatinib-resistant FLT3 mutants don&apos;t bind ponatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway11">
 <bp:pathwayOrder rdf:resource="#PathwayStep19" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction9" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence19" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">gilteritinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Gilteritinib is a second-generation type I tyrosine kinase inhibitor with activity against FLT3 (reviewed in Daver et al, 2019; Hassanein et l, 2016; Lim et al, 2017; Luxkin et al, 2017). This pathway describes FLT3 mutants that are resistant to inhibition by gilteritinib.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction14">
 <bp:evidence rdf:resource="#Evidence30" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">crenolanib-resistant FLT3 mutants don&apos;t bind crenolanib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep12">
 <bp:stepProcess rdf:resource="#Pathway8" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction11">
 <bp:evidence rdf:resource="#Evidence24" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">semaxanib-resistant FLT3 mutants don&apos;t bind semaxanib&lt;br&gt;</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway16">
 <bp:pathwayOrder rdf:resource="#PathwayStep29" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction14" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence29" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">crenolanib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Crenolanib is a second-generation type I tyrosine kinase inhibitor with activity against FLT3 (reviewed in Daver et al, 2019; Staudt et al, 2018; Larrosa-Garcia and Bauer, 2017). This pathway describes FLT3 mutants that are resistant to crenolanib-mediated inhibition.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep13">
 <bp:stepProcess rdf:resource="#BiochemicalReaction6" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction12">
 <bp:evidence rdf:resource="#Evidence26" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">linafinib-resistant FLT3 mutants don&apos;t bind linifanib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway17">
 <bp:pathwayOrder rdf:resource="#PathwayStep38" />
 <bp:pathwayOrder rdf:resource="#PathwayStep39" />
 <bp:pathwayOrder rdf:resource="#PathwayStep36" />
 <bp:pathwayOrder rdf:resource="#PathwayStep47" />
 <bp:pathwayOrder rdf:resource="#PathwayStep37" />
 <bp:pathwayOrder rdf:resource="#PathwayStep48" />
 <bp:pathwayOrder rdf:resource="#PathwayStep41" />
 <bp:pathwayOrder rdf:resource="#PathwayStep31" />
 <bp:pathwayOrder rdf:resource="#PathwayStep42" />
 <bp:pathwayOrder rdf:resource="#PathwayStep40" />
 <bp:pathwayOrder rdf:resource="#PathwayStep34" />
 <bp:pathwayOrder rdf:resource="#PathwayStep45" />
 <bp:pathwayOrder rdf:resource="#PathwayStep35" />
 <bp:pathwayOrder rdf:resource="#PathwayStep46" />
 <bp:pathwayOrder rdf:resource="#PathwayStep32" />
 <bp:pathwayOrder rdf:resource="#PathwayStep43" />
 <bp:pathwayOrder rdf:resource="#PathwayStep33" />
 <bp:pathwayOrder rdf:resource="#PathwayStep44" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction19" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction17" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction28" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction18" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction29" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction15" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction26" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction16" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction27" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction24" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction25" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction22" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction23" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction20" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction31" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction21" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction32" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction30" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence31" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FLT3 fusion proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In addition to internal tandem duplications and activating point mutations, FLT3 is also subject at low frequency to translocations that generate fusion proteins. These fusion proteins occur in some chronic myeloid leukemias as well as myeloid neoplasms with eosinophilia, and generate constitutively active proteins by virtue of fusing a N-terminal partner encoding a dimerization domain with the intracellular region of FLT3 (reviewed in Reiter and Gotlib, 2017; Kazi and Roonstrand, 2019). To date, 6 fusion partner genes of FLT3 have been identified: ETV6, TRIP11, MYO18A, SPTBN1, GOLGB1 and ZMYM2 (Balwin et al, 2007; Vu et al, 2006; Walz et al, 2011; Falchi et al, 2014; Chung et al, 2017; Troadec et al, 2017; Grand et al, 2007; Jawhar et al, 2017; Zhang et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep10">
 <bp:stepProcess rdf:resource="#Pathway7" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway14">
 <bp:pathwayOrder rdf:resource="#PathwayStep25" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction12" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence25" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">linifanib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Linifanib is a type I tyrosine kinase inhibitor with activity against a broad range of receptor tyrosine kinases including FLT3. This pathway describes FLT3 mutants that are resistant to inhibition by linifanib (Hernandez-Davies et al, 2011; Nguyen et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep11">
 <bp:stepProcess rdf:resource="#BiochemicalReaction5" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction10">
 <bp:evidence rdf:resource="#Evidence22" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">quizartinib-resistant FLT3 mutants don&apos;t bind quizartinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway15">
 <bp:pathwayOrder rdf:resource="#PathwayStep27" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction13" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence27" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ponatinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ponatinib is a first generation tyrosine kinase inhibitor with activity against a broad range of receptor tyrosine kinases, including FLT3 (reviewed Pemmeraju et al, 2014; Kazi and Roonstrand, 2019). This pathway describes FLT3 mutants that are resistant to inhibition by ponatinib.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway18">
 <bp:pathwayOrder rdf:resource="#PathwayStep50" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction33" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence50" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 signaling by CBL mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Missense and splicing mutants have been identified in the E3 ubiquitin ligase CBL in a number of cancers including acute and chronic myeloid leukemias, among others. These cancers show elevated signaling through FLT3 as a result of impaired CBL-mediated downregulation of the receptor (Sargin et al, 2007; Reindl et al, 2009; Caligiuri et al, 2007; Abbas et al, 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway19">
 <bp:pathwayOrder rdf:resource="#PathwayStep52" />
 <bp:pathwayOrder rdf:resource="#PathwayStep53" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction35" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction34" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence52" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants bind TKIs</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant signaling by activated forms of FLT3 can be inhibited by tyrosine kinase inhibitors (TKIs). FLT3 receptors are class III receptor tyrosine kinase receptors, also known as dual-switch. Dual-switch receptors are activated through a series of phosphorylation and conformational changes that move the receptor from the inactive form to the fully activated form. Type II TKIs bind to the inactive form of the receptor at a site adjacent to the ATP-binding cleft, while type I TKIs bind to the active form (reviewed in Klug et al, 2018; Daver et al, 2019).  FLT3 internal tandem duplications (ITDs) are found in ~25-30% of acute myeloid leukemias, and are present at lower frequencies in other cancers (reviewed in Kazi and Roostrand, 2019; Patnaik et al, 2018). These ITDs generally occur in a tyrosine-rich region of exon 14, encoding the juxtamembrane domain region of the protein; at a lower frequency, ITDs are found in the first tyrosine kinase domain (TKD1). In addition to ITDs, a number of point mutations in the juxtamembrane domain have also been identified. Juxtamembrane domain mutations affect an autoinhibitory loop, shifting the equilibrium of the receptor towards the activated state; despite this, however, juxtamembrane domain mutants remain predominantly in the inactive state and as such are susceptible to inhibition by type II TKIs (reviewed in Patnaik et al, 2018; Kazi and Roonstrand et al, 2019).   Activation loop mutations more strongly favor the active conformation of the receptor and are susceptible to inhibition by both type II and type I TKIs. The most prevalent FLT3 mutation, D835Y, promotes the active conformation strongly enough to be resistant to type II TKIs (Patnaik et al, 2017; Klug et al, 2018; Daver et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep16">
 <bp:stepProcess rdf:resource="#Pathway10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep17">
 <bp:stepProcess rdf:resource="#BiochemicalReaction8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep14">
 <bp:stepProcess rdf:resource="#Pathway9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep15">
 <bp:stepProcess rdf:resource="#BiochemicalReaction7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep18">
 <bp:stepProcess rdf:resource="#Pathway11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep19">
 <bp:stepProcess rdf:resource="#BiochemicalReaction9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep20">
 <bp:stepProcess rdf:resource="#Pathway12" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep23">
 <bp:stepProcess rdf:resource="#BiochemicalReaction11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep24">
 <bp:stepProcess rdf:resource="#Pathway14" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep21">
 <bp:stepProcess rdf:resource="#BiochemicalReaction10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep22">
 <bp:stepProcess rdf:resource="#Pathway13" />
</bp:PathwayStep>

<bp:BioSource rdf:ID="BioSource1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo sapiens</bp:name>
</bp:BioSource>

<bp:Evidence rdf:ID="Evidence45">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence44">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence47">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence46">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence49">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence48">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction39">
 <bp:evidence rdf:resource="#Evidence59" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants:GRB2:p-Y-GAB2 binds PTPN11</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction37">
 <bp:evidence rdf:resource="#Evidence57" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants recruit PIK3CA through PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction38">
 <bp:evidence rdf:resource="#Evidence58" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of FLT3 mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction35">
 <bp:evidence rdf:resource="#Evidence54" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT mutants bind type I TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction36">
 <bp:evidence rdf:resource="#Evidence56" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants:GRB2:SOS1-mediated nucleotide exchange on RAS</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence41">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction33">
 <bp:evidence rdf:resource="#Evidence51" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CBL mutants don&apos;t ubiquitinate FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence40">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction34">
 <bp:evidence rdf:resource="#Evidence53" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT mutants bind type II TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence43">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction31">
 <bp:evidence rdf:resource="#Evidence48" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions:GRB2 bind GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence42">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction32">
 <bp:evidence rdf:resource="#Evidence49" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 translocates to nucleus downstream of mutant FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction30">
 <bp:evidence rdf:resource="#Evidence47" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SOS1-mediated nucleotide exchange of RAS downstream of FLT3 fusion mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence56">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence55">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence58">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence57">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway20">
 <bp:pathwayOrder rdf:resource="#PathwayStep61" />
 <bp:pathwayOrder rdf:resource="#PathwayStep62" />
 <bp:pathwayOrder rdf:resource="#PathwayStep56" />
 <bp:pathwayOrder rdf:resource="#PathwayStep78" />
 <bp:pathwayOrder rdf:resource="#PathwayStep57" />
 <bp:pathwayOrder rdf:resource="#PathwayStep79" />
 <bp:pathwayOrder rdf:resource="#PathwayStep55" />
 <bp:pathwayOrder rdf:resource="#PathwayStep77" />
 <bp:pathwayOrder rdf:resource="#PathwayStep58" />
 <bp:pathwayOrder rdf:resource="#PathwayStep59" />
 <bp:pathwayOrder rdf:resource="#PathwayStep60" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction37" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction59" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction38" />
 <bp:pathwayComponent rdf:resource="#Pathway21" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction57" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction36" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction58" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction42" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction40" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction41" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction39" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence55" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FLT3 ITD and TKD mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 is subject to internal tandem duplications (ITDs) of lengths varying from 3 to 1236 base pairs (Nakao et al, 1996; Kiyoi et al 1997, Meshinchi et al, 2008; reviewed in Kazi and Roonstrand, 2019). These ITDs are generally found in the juxtamembrane domain, or more rarely, the first tyrosine kinase domain (TKD) and disrupt the autoinhibitory loop of the receptor, constitutively activating it (Kiyoi et al, 2002; Griffith et al, 2004; reviewed in Lagunas-Rangel and Chavez-Valencia, 2017; Kazi and Roonstrand, 2019). FLT3 ITDs are found in ~25% of acute myeloid leukemias (AMLs) and represent the most frequent mutation of this cancer (reviewed in Kazi and Roonstrand, 2019, Klug et al, 2018) At lower frequency, FLT3 is subject to activating point mutations (~7% of AML cases). These mutations tend to cluster in the TKD, with mutation of the activation loop residue D835 and the gatekeeper F691 residue the most common sites (Griffin et al, 2001; Jiang et al, 2004; reviewed in Kazi and Roonstrand, 2019).  FLT3 ITD and TKD mutants support cellular transformation through activation of downstream signaling pathways such as the MAP kinase, PI3K/AKT and STAT5 cascades. There is some debate about the extent to which the pathways activated by the ITD and TKD mutants are distinct, with some evidence that STAT5 signaling, in particular, is more characteristic of FLT3 ITD activation (Hayakawa et al, 2000; Choudhary et al, 2005; Grundler et al, 2005; Choudhary et al, 2007; Yoshimoto et al, 2009; Leischner et al, 2012; Janke et al, 2014; Marhall et al, 2018; reviewed in Chan, 2011; Kazi and Roonstrand, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence59">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction28">
 <bp:evidence rdf:resource="#Evidence45" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and STAT5-dependent CDKN1A gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction29">
 <bp:evidence rdf:resource="#Evidence46" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated FLT3 fusions bind GRB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction26">
 <bp:evidence rdf:resource="#Evidence43" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 binds the NOX4 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction27">
 <bp:evidence rdf:resource="#Evidence44" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 binds the CDKN1A gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction24">
 <bp:evidence rdf:resource="#Evidence41" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and NOX4-dependent H2O2 production</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence50">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway21">
 <bp:pathwayOrder rdf:resource="#PathwayStep69" />
 <bp:pathwayOrder rdf:resource="#PathwayStep63" />
 <bp:pathwayOrder rdf:resource="#PathwayStep74" />
 <bp:pathwayOrder rdf:resource="#PathwayStep64" />
 <bp:pathwayOrder rdf:resource="#PathwayStep75" />
 <bp:pathwayOrder rdf:resource="#PathwayStep72" />
 <bp:pathwayOrder rdf:resource="#PathwayStep73" />
 <bp:pathwayOrder rdf:resource="#PathwayStep67" />
 <bp:pathwayOrder rdf:resource="#PathwayStep68" />
 <bp:pathwayOrder rdf:resource="#PathwayStep65" />
 <bp:pathwayOrder rdf:resource="#PathwayStep76" />
 <bp:pathwayOrder rdf:resource="#PathwayStep66" />
 <bp:pathwayOrder rdf:resource="#PathwayStep70" />
 <bp:pathwayOrder rdf:resource="#PathwayStep71" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction48" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction49" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction46" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction47" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction44" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction55" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction45" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction56" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction53" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction43" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction54" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction51" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction52" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction50" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence63" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT5 activation downstream of FLT3 ITD mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT5 signaling appears to be preferentially activated downstream of FLT3 ITD mutants relative to the wild-type or FLT3 TKD mutants, although this is subject to some debate (Choudhary et al, 2005; Reindl et al, 2006; Bagrintseva et al, 2005; Grundler et al, 2003; Choudhary et al, 2007; Marhall et al, 2018; reviewed in Choudhary et al, 2005). STAT5 activation contributes to oncogenesis by promoting the transcription of a number of factors involved in regulating cell cycle progression, proliferation and apoptosis, among others (Kim et al, 2005; Nabinger et al, 2013; Takahashi et al, 2004; Godfrey et al, 2012; Hayakawa et al, 2000; reviewed in Murphy and Rani, 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction25">
 <bp:evidence rdf:resource="#Evidence42" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions:GRB2 bind SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction22">
 <bp:evidence rdf:resource="#Evidence39" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusion dimers autophosphorylate</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence52">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction23">
 <bp:evidence rdf:resource="#Evidence40" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT5-dependent PIM1 gene expression downstream of FLT3 ITD and fusion mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence51">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction20">
 <bp:evidence rdf:resource="#Evidence37" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions phosphorylate GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence54">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction21">
 <bp:evidence rdf:resource="#Evidence38" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and STAT5-dependent NOX4 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence53">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence23">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence22">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence25">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence24">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence27">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence26">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence29">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence28">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction7">
 <bp:evidence rdf:resource="#Evidence16" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">sorafenib-resistant FLT3 mutants don&apos;t bind sorafenib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction59">
 <bp:evidence rdf:resource="#Evidence80" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants phosphorylate GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction6">
 <bp:evidence rdf:resource="#Evidence14" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">tamatinib-resistant FLT3 mutants don&apos;t bind tamatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction9">
 <bp:evidence rdf:resource="#Evidence20" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">gilteritinib-resistant FLT3 mutants don&apos;t bind gilteritinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction57">
 <bp:evidence rdf:resource="#Evidence78" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutant dimers bind GRB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction8">
 <bp:evidence rdf:resource="#Evidence18" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">lestaurtinib-resistant FLT3 mutants don&apos;t bind lestaurtinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction58">
 <bp:evidence rdf:resource="#Evidence79" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants recruit PIK3R1 through phosphorylated GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction3">
 <bp:evidence rdf:resource="#Evidence8" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">sunitinib-resistant FLT3 mutants don&apos;t bind sunitinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction55">
 <bp:evidence rdf:resource="#Evidence76" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD mutants bind STAT5 through GAB2:PTPN11</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction2">
 <bp:evidence rdf:resource="#Evidence6" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">midostaurin-resistant FLT3 mutants don&apos;t bind midostaurin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction56">
 <bp:evidence rdf:resource="#Evidence77" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 translocates to nucleus downstream of mutant FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction5">
 <bp:evidence rdf:resource="#Evidence12" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">tandutinib-resistant FLT3 mutants don&apos;t bind tandutinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence21">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction53">
 <bp:evidence rdf:resource="#Evidence74" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and STAT5-dependent CDKN1A gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction4">
 <bp:evidence rdf:resource="#Evidence10" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pexidartinib-resistant FLT3 mutants don&apos;t bind pexidartinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence20">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction54">
 <bp:evidence rdf:resource="#Evidence75" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD mutants phosphorylate STAT5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction51">
 <bp:evidence rdf:resource="#Evidence72" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PTPN11:p-STAT5 dissociates from mutant FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction52">
 <bp:evidence rdf:resource="#Evidence73" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 binds the CDKN1A gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1">
 <bp:evidence rdf:resource="#Evidence4" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KW2449-resistant FLT3 mutants don&apos;t bind KW2449</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction50">
 <bp:evidence rdf:resource="#Evidence71" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 binds the NOX4 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence34">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence33">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence36">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence35">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence38">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence37">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence39">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction48">
 <bp:evidence rdf:resource="#Evidence69" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and NOX4-dependent H2O2 production</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction49">
 <bp:evidence rdf:resource="#Evidence70" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PTPN11:p-STAT5 translocates to nucleus downstream of mutant FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction46">
 <bp:evidence rdf:resource="#Evidence67" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT5-dependent PIM1 gene expression downstream of FLT3 ITD and fusion mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction47">
 <bp:evidence rdf:resource="#Evidence68" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PTPN11:p-STAT5 binds BCL2L1 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence30">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction44">
 <bp:evidence rdf:resource="#Evidence65" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and STAT5-dependent NOX4 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction45">
 <bp:evidence rdf:resource="#Evidence66" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and STAT5-dependent BCL2L1 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence32">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction42">
 <bp:evidence rdf:resource="#Evidence62" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants:GRB2 bind GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence31">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction43">
 <bp:evidence rdf:resource="#Evidence64" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 dissociates from mutant FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction40">
 <bp:evidence rdf:resource="#Evidence60" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive phosphorylation of FLT3 mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction41">
 <bp:evidence rdf:resource="#Evidence61" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutant dimers:GRB2 bind SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep69">
 <bp:stepProcess rdf:resource="#BiochemicalReaction49" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep74">
 <bp:stepProcess rdf:resource="#Catalysis9" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction54" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep75">
 <bp:stepProcess rdf:resource="#BiochemicalReaction55" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence80">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence8">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep72">
 <bp:stepProcess rdf:resource="#BiochemicalReaction52" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence9">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep73">
 <bp:stepProcess rdf:resource="#BiochemicalReaction53" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep78">
 <bp:stepProcess rdf:resource="#BiochemicalReaction58" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep79">
 <bp:stepProcess rdf:resource="#BiochemicalReaction59" />
 <bp:stepProcess rdf:resource="#Catalysis10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep76">
 <bp:stepProcess rdf:resource="#BiochemicalReaction56" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep77">
 <bp:stepProcess rdf:resource="#BiochemicalReaction57" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence3">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence6">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep70">
 <bp:stepProcess rdf:resource="#BiochemicalReaction50" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence7">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep71">
 <bp:stepProcess rdf:resource="#BiochemicalReaction51" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence4">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence5">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis10">
 <bp:controlled rdf:resource="#BiochemicalReaction59" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence67">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence66">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence69">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence68">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence61">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence60">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1">
 <bp:stepProcess rdf:resource="#Pathway2" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence63">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2">
 <bp:stepProcess rdf:resource="#Pathway3" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence62">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep3">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence65">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep4">
 <bp:stepProcess rdf:resource="#Pathway4" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence64">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep5">
 <bp:stepProcess rdf:resource="#BiochemicalReaction2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep6">
 <bp:stepProcess rdf:resource="#Pathway5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep7">
 <bp:stepProcess rdf:resource="#BiochemicalReaction3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep8">
 <bp:stepProcess rdf:resource="#Pathway6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep9">
 <bp:stepProcess rdf:resource="#BiochemicalReaction4" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence78">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence77">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence79">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis4">
 <bp:controlled rdf:resource="#BiochemicalReaction30" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence70">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis5">
 <bp:controlled rdf:resource="#BiochemicalReaction33" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis6">
 <bp:controlled rdf:resource="#BiochemicalReaction36" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence72">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis7">
 <bp:controlled rdf:resource="#BiochemicalReaction40" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence71">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis8">
 <bp:controlled rdf:resource="#BiochemicalReaction48" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence74">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence73">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis9">
 <bp:controlled rdf:resource="#BiochemicalReaction54" />
</bp:Catalysis>

<bp:Provenance rdf:ID="Provenance1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reactome</bp:name>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">http://www.reactome.org</bp:comment>
</bp:Provenance>

<bp:Evidence rdf:ID="Evidence76">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence75">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis1">
 <bp:controlled rdf:resource="#BiochemicalReaction20" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis2">
 <bp:controlled rdf:resource="#BiochemicalReaction22" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis3">
 <bp:controlled rdf:resource="#BiochemicalReaction24" />
</bp:Catalysis>
</rdf:RDF>